Sage Therapeutics (SAGE +2.4%) Q3 results: Revenues: $3.6M; ZULRESSO (brexanolone) CIV injection revenues: $1.5M; Collaboration revenues from Shionogi & Co.: $2.1M.
Net loss: ($180M) (-46.3%); loss/share: ($3.48) (-32.3%); Quick Assets: $1,124.6M (+21.6%).
Enrollment completed in SAGE-217 Phase 3 MOUNTAIN and SHORELINE studies with topline data expected in 4Q 2019 and 2020, respectively.
The company plans to expand pipeline with two new GABA and NMDA clinical-stage assets.
Previously: Sage Therapeutics EPS misses by $0.07, beats on revenue (Nov. 12)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.